Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma - NICE TAG TA446

1.1Brentuximab vedotin is recommended as an option for treating CD30‑positive Hodgkin lymphoma in adults, only if:

• they have relapsed or refractory disease after autologous stem cell transplant and

• the company provides brentuximab vedotin at the price agreed with NHS England in the commercial access agreement.

1.2 Brentuximab vedotin is recommended for use within the Cancer Drugs Fund as an option for treating CD30‑positive Hodgkin lymphoma in adults, only if:

• they have relapsed or refractory disease after at least 2 previous therapies and

• they cannot have autologous stem cell transplant or multi-agent chemotherapy and

• the conditions of the managed access agreement are followed.

1.3 These recommendations are not intended to affect treatment with brentuximab vedotin that was started in the NHS before this guidance was published. Adults having treatment outside these recommendations may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.

https://www.nice.org.uk/guidance/ta446